- Main
MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell–intrinsic Amplification of Type I IFN Signaling
- Ghukasyan, R;
- Liang, K;
- Chau, K;
- Li, L;
- Chan, C;
- Abt, ER;
- Le, T;
- Park, JY;
- Wu, N;
- Premji, A;
- Damoiseaux, R;
- Luu, T;
- Labora, A;
- Rashid, K;
- Link, JM;
- Radu, CG;
- Donahue, TR
Published Web Location
https://doi.org/10.1158/1078-0432.CCR-22-3322Abstract
Purpose: Stimulator of interferon genes (STING) agonists are Results: We found that MEK inhibitors caused the greatest currently in development for treatment of solid tumors, including synergy with diABZI and that this effect was most pronounced pancreatic ductal adenocarcinoma (PDAC). Response rates to in cells with high STING expression. MEK inhibition enhanced STING agonists alone have been promising yet modest, and com-the ability of STING agonism to induce type I IFN-dependent bination therapies will likely be required to elicit their full potency. cell death in vitro and tumor regression in vivo. We parsed We sought to identify combination therapies and mechanisms that NFkB-dependent and NFkB-independent mechanisms that augment the tumor cell–intrinsic effect of therapeutically relevant mediate STING-driven type I IFN production and show that STING agonists apart from their known effects on tumor immunity. MEK signaling inhibits this effect by suppressing NFkB Experimental Design: We screened 430 kinase inhibitors to activation. identify synergistic effectors of tumor cell death with diABZI, an Conclusions: Our results highlight the cytotoxic effects of intravenously administered and systemically available STING ago-STING agonism on PDAC cells that are independent of tumor nist. We deciphered the mechanisms of synergy with STING agonism immunity and that these therapeutic benefits of STING agonism that cause tumor cell death in vitro and tumor regression in vivo. can be synergistically enhanced by MEK inhibition.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.